NEJM March 26, 2026: Volume 394, Issue 12 – Latest Research

A new combination therapy—atezolizumab plus FOLFOX—shows promise for individuals diagnosed with Stage III mismatch repair-deficient (dMMR) colon cancer, according to research published March 26, 2026, in the New England Journal of Medicine. The study, detailed in Volume 394, Issue 12, pages 1155-1166, offers a potential advancement in treating this specific subtype of colorectal cancer, which often proves resistant to standard treatments.

Understanding Mismatch Repair Deficiency and Colon Cancer

Colorectal cancer is a leading cause of cancer-related deaths worldwide. A significant factor influencing treatment outcomes is the status of mismatch repair (MMR) genes. These genes are responsible for correcting errors that occur during DNA replication. When MMR genes are deficient—meaning they don’t function properly—errors accumulate, leading to genetic instability and an increased risk of cancer. Approximately 15% of colorectal cancers are dMMR, and these tumors tend to be more aggressive and have different responses to treatment compared to MMR-proficient (pMMR) tumors.

Stage III colon cancer indicates that the cancer has spread beyond the colon wall to nearby lymph nodes, but not to distant organs. This stage requires a multi-faceted treatment approach, typically involving surgery to remove the tumor, followed by adjuvant chemotherapy—chemotherapy given after surgery to kill any remaining cancer cells and reduce the risk of recurrence.

The Atezolizumab and FOLFOX Combination

The recent study investigated the efficacy of adding atezolizumab, an immunotherapy drug, to the standard FOLFOX chemotherapy regimen. FOLFOX is a combination of three drugs: folinic acid, fluorouracil, and oxaliplatin. Immunotherapy works by boosting the body’s own immune system to recognize and attack cancer cells. Atezolizumab is a type of immunotherapy called a PD-1 inhibitor, which blocks a protein that prevents immune cells from attacking cancer cells.

The trial evaluated whether the addition of atezolizumab to FOLFOX would improve disease-free survival—the length of time after treatment during which a patient remains free of cancer—in patients with Stage III dMMR colon cancer. While the full details of the study design, including sample size and specific endpoints, are available in the New England Journal of Medicine publication, the findings suggest a potential benefit from this combined approach.

What the Findings Mean for Patients

The study’s results indicate that adding atezolizumab to FOLFOX may improve disease-free survival in patients with Stage III dMMR colon cancer. However, it’s crucial to understand that this research represents one step in a continuous process of medical discovery. The study does not definitively prove a cure, nor does it establish a new standard of care immediately. Further research is needed to confirm these findings and to determine the long-term effects of this combination therapy.

It’s as well vital to note that immunotherapy drugs can have side effects, ranging from mild to severe. These side effects can affect various organs and systems in the body. Patients considering this treatment option should discuss the potential benefits and risks with their oncologist to build an informed decision.

Contextualizing the Results: Immunotherapy in Colorectal Cancer

Immunotherapy has revolutionized cancer treatment for many types of cancer, but its effectiveness in colorectal cancer has been more limited, particularly in tumors that are not dMMR. DMMR tumors, due to their high level of genetic mutation, are more likely to respond to immunotherapy. Here’s since the increased number of mutations creates more “targets” for the immune system to recognize.

The National Cancer Institute provides comprehensive information on colorectal cancer, including risk factors, symptoms, diagnosis, and treatment options. Understanding the specific characteristics of a patient’s tumor, such as its MMR status, is essential for tailoring treatment to maximize its effectiveness.

Trial Endpoints and Uncertainty

The primary endpoint of the study was disease-free survival, a common measure of treatment success in cancer trials. However, disease-free survival is not a perfect measure. It doesn’t share us whether the treatment improves overall survival—how long patients live after diagnosis—or quality of life. The study’s findings may be influenced by factors such as patient selection, treatment adherence, and the definition of disease recurrence. The New England Journal of Medicine publication will contain a detailed discussion of these limitations.

The Evolving Landscape of Colorectal Cancer Treatment

The treatment of colorectal cancer is constantly evolving. Researchers are continually exploring new therapies and combinations of therapies to improve outcomes for patients. In addition to immunotherapy, other promising areas of research include targeted therapies, which target specific molecules involved in cancer growth and spread, and personalized medicine, which tailors treatment to the individual characteristics of each patient’s tumor.

The American Cancer Society offers detailed information on colorectal cancer, including the latest research and treatment advances. Staying informed about these developments can empower patients and their families to make informed decisions about their care.

What Comes Next: Surveillance and Further Research

The findings from this study will likely prompt further research to confirm its results and to explore the optimal use of atezolizumab plus FOLFOX in the treatment of Stage III dMMR colon cancer. This may include larger clinical trials, studies to identify biomarkers that predict response to treatment, and investigations into the long-term effects of this combination therapy.

Ongoing surveillance of patients treated with this regimen will also be crucial to monitor for any potential side effects and to assess the durability of the treatment response. Health authorities, such as the National Comprehensive Cancer Network (NCCN), will likely review the data and update their guidelines accordingly as more information becomes available. Patients should continue to follow the advice of their healthcare team and participate in regular follow-up appointments.